Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Emerging Immunotargets and Immunotherapies in Prostate Cancer

Author(s): Rodolfo Montironi, Matteo Santoni, Valeria Sotte, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana, Holger Moch, Rossana Berardi and Marina Scarpelli

Volume 17 , Issue 7 , 2016

Page: [777 - 782] Pages: 6

DOI: 10.2174/1389450117666160217123304

Price: $65

Abstract

Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.

Keywords: Immunotherapy, programmed death-1, prognosis, prostate cancer, vaccines.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy